drugset
drugset / Trial / NCT06162169

A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects

NCT06162169 ↗

Phase 1 Completed 66 enrolled Allist Pharmaceuticals, Inc.
Non-randomizedParallel-groupOpen-labelOther

Summary

This is a phase I study to evaluate drug-drug interactions (DDIs) of JAB-21822 as a perpetrator combined with midazolam , rosuvastatin, and digoxin and to evaluate DDIs of JAB-21822 as a victim combined with itraconazole， rifampicin， and omeprazole in healthy subjects.

Timeline

Start
2023-11-25
Primary completion
2024-02-20
Completion
2024-02-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Digoxin Other / unclassified — Oral
Subject Glecirasib Small molecule — Oral
Subject Itraconazole Small molecule — Oral
Subject Midazolam Small molecule — Oral
Subject Omeprazole Other / unclassified — Oral
Subject Rifampicin Small molecule — Oral
Subject Rosuvastatin Small molecule — Oral

Indications

No indication recorded.